CL2023003003A1 - Tratamiento y diagnóstico de trastornos inflamatorios - Google Patents
Tratamiento y diagnóstico de trastornos inflamatoriosInfo
- Publication number
- CL2023003003A1 CL2023003003A1 CL2023003003A CL2023003003A CL2023003003A1 CL 2023003003 A1 CL2023003003 A1 CL 2023003003A1 CL 2023003003 A CL2023003003 A CL 2023003003A CL 2023003003 A CL2023003003 A CL 2023003003A CL 2023003003 A1 CL2023003003 A1 CL 2023003003A1
- Authority
- CL
- Chile
- Prior art keywords
- subject
- inflammatory disorder
- diagnosis
- treatment
- inflammatory disorders
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Método para tratar un trastorno inflamatorio en un sujeto, que comprende administrar al sujeto que lo necesita una molécula de ácido nucleico para inhibir la expresión de Hom-1. Específicamente, la molécula de ácido nucleico es un agente de ARNi o un oligonucleótido morfolino antisentido. Además, se describe un método para seleccionar un agente terapéutico para un trastorno inflamatorio en un sujeto, o monitorear la eficacia de un agente terapéutico para un trastorno inflamatorio en un sujeto, que comprende detectar el nivel de expresión de Hom-1 en una muestra de tejido inflamado obtenida del sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662291271P | 2016-02-04 | 2016-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023003003A1 true CL2023003003A1 (es) | 2024-04-19 |
Family
ID=59499992
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002097A CL2018002097A1 (es) | 2016-02-04 | 2018-08-03 | Tratamiento y diagnóstico de desórdenes inflamatorios |
CL2021003543A CL2021003543A1 (es) | 2016-02-04 | 2021-12-29 | Tratamiento y diagnóstico de desórdenes inflamatorios (divisional de la solicitud no. 201802097) |
CL2023003003A CL2023003003A1 (es) | 2016-02-04 | 2023-10-06 | Tratamiento y diagnóstico de trastornos inflamatorios |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002097A CL2018002097A1 (es) | 2016-02-04 | 2018-08-03 | Tratamiento y diagnóstico de desórdenes inflamatorios |
CL2021003543A CL2021003543A1 (es) | 2016-02-04 | 2021-12-29 | Tratamiento y diagnóstico de desórdenes inflamatorios (divisional de la solicitud no. 201802097) |
Country Status (13)
Country | Link |
---|---|
US (2) | US11268095B2 (es) |
EP (1) | EP3411479A4 (es) |
JP (2) | JP2019512018A (es) |
KR (1) | KR20180109985A (es) |
CN (1) | CN108779461A (es) |
AU (2) | AU2017213744B2 (es) |
CA (1) | CA3013898A1 (es) |
CL (3) | CL2018002097A1 (es) |
IL (2) | IL260987B1 (es) |
MX (2) | MX2018009542A (es) |
MY (1) | MY194135A (es) |
SG (2) | SG11201806636SA (es) |
WO (1) | WO2017136322A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111528842B (zh) * | 2020-05-26 | 2023-01-03 | 复嶂环洲生物科技(上海)有限公司 | 基于生理和行为指标的帕金森病症状定量化评估方法 |
CA3225436A1 (en) * | 2021-06-23 | 2022-12-29 | Enclear Therapies, Inc. | Method of regulating gene expression |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035790A1 (en) | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
JPWO2005070964A1 (ja) | 2004-01-27 | 2008-01-17 | 株式会社医学生物学研究所 | 単球の単離方法 |
US7994126B2 (en) * | 2006-02-22 | 2011-08-09 | Zhenglun Zhu | Treatment of cellular proliferative disorders with compositions comprising Hom polypeptide (also known as Xom, VENTX2) |
US8741865B2 (en) * | 2009-07-15 | 2014-06-03 | Zhenglun Zhu | Treatment of immune disorders with Hom-1 inhibitors |
WO2012071513A2 (en) * | 2010-11-24 | 2012-05-31 | Hong Gao | Expanding hematopoietic stem cells |
WO2012170979A1 (en) * | 2011-06-10 | 2012-12-13 | Zhenglun Zhu | Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof |
WO2014093773A1 (en) | 2012-12-14 | 2014-06-19 | The Brigham And Women's Hospital, Inc. | Methods and assays relating to macrophage differentiation |
CN105473710B (zh) * | 2013-04-10 | 2019-08-23 | 朱正伦 | 同源盒转录因子VentX调控人树突状细胞的分化和成熟 |
US9428748B2 (en) * | 2013-06-17 | 2016-08-30 | Hong Gao | Method of expanding hematopoietic stem cells |
-
2017
- 2017-01-31 MX MX2018009542A patent/MX2018009542A/es unknown
- 2017-01-31 IL IL260987A patent/IL260987B1/en unknown
- 2017-01-31 WO PCT/US2017/015775 patent/WO2017136322A1/en active Application Filing
- 2017-01-31 JP JP2018560436A patent/JP2019512018A/ja active Pending
- 2017-01-31 SG SG11201806636SA patent/SG11201806636SA/en unknown
- 2017-01-31 EP EP17748003.5A patent/EP3411479A4/en active Pending
- 2017-01-31 SG SG10201913129QA patent/SG10201913129QA/en unknown
- 2017-01-31 IL IL311968A patent/IL311968A/en unknown
- 2017-01-31 MY MYPI2018702738A patent/MY194135A/en unknown
- 2017-01-31 CA CA3013898A patent/CA3013898A1/en active Pending
- 2017-01-31 CN CN201780016917.2A patent/CN108779461A/zh active Pending
- 2017-01-31 AU AU2017213744A patent/AU2017213744B2/en active Active
- 2017-01-31 KR KR1020187025087A patent/KR20180109985A/ko unknown
- 2017-01-31 US US16/075,479 patent/US11268095B2/en active Active
-
2018
- 2018-08-03 CL CL2018002097A patent/CL2018002097A1/es unknown
- 2018-08-03 MX MX2022010890A patent/MX2022010890A/es unknown
-
2021
- 2021-12-29 CL CL2021003543A patent/CL2021003543A1/es unknown
-
2022
- 2022-02-18 US US17/675,800 patent/US20220177892A1/en active Pending
- 2022-09-09 JP JP2022143467A patent/JP2022180437A/ja active Pending
-
2023
- 2023-09-22 AU AU2023233180A patent/AU2023233180A1/en active Pending
- 2023-10-06 CL CL2023003003A patent/CL2023003003A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021003543A1 (es) | 2022-08-19 |
JP2019512018A (ja) | 2019-05-09 |
US11268095B2 (en) | 2022-03-08 |
MY194135A (en) | 2022-11-14 |
SG10201913129QA (en) | 2020-02-27 |
CL2018002097A1 (es) | 2018-12-21 |
EP3411479A1 (en) | 2018-12-12 |
US20220177892A1 (en) | 2022-06-09 |
KR20180109985A (ko) | 2018-10-08 |
WO2017136322A1 (en) | 2017-08-10 |
CA3013898A1 (en) | 2017-08-10 |
AU2023233180A1 (en) | 2023-12-14 |
SG11201806636SA (en) | 2018-09-27 |
AU2017213744A1 (en) | 2018-08-30 |
IL311968A (en) | 2024-06-01 |
EP3411479A4 (en) | 2019-09-18 |
IL260987A (en) | 2018-09-20 |
IL260987B1 (en) | 2024-05-01 |
MX2022010890A (es) | 2022-09-27 |
JP2022180437A (ja) | 2022-12-06 |
AU2017213744B2 (en) | 2023-06-22 |
US20190085336A1 (en) | 2019-03-21 |
CN108779461A (zh) | 2018-11-09 |
MX2018009542A (es) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023003003A1 (es) | Tratamiento y diagnóstico de trastornos inflamatorios | |
CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
UY40039A (es) | COMPOSICIONES DE ARNi DEL COMPONENTE DEL COMPLEMENTO C5 Y MÉTODOS PARA SU USO | |
EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
CR20110128A (es) | Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha | |
BR112013028808A2 (pt) | métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada | |
DOP2021000126A (es) | COMPOSICIONES DE AGENTE DE ARNi DE PROTEÍNA PRECURSORA DE AMILOIDE (APP) Y MÉTODO DE USO DE LAS MISMAS | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
AR081874A1 (es) | Metodo para predecir eficacia a un regimen terapeutico en un paciente con adenocarcinomas mediante la expresion de un gen reparador de adn (msh3) | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
EA201790444A1 (ru) | Hsp90-направленная визуализация и терапия воспаления и инфекции | |
BR112016024332A2 (pt) | métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização | |
EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
MX2017008462A (es) | Metodos para utilizar oligonucleotidos antisentido para smad7. | |
BR112012026224A2 (pt) | métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia | |
BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
TR201900665T4 (tr) | Diyabetik nefropatinin tedavi yöntemi. | |
BR112013025197A2 (pt) | métodos para tratar doença de alzheimer e para avaliar a eficáca de uma terapia destinada a tratar doença de alzheimer | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
WO2014126796A3 (en) | Methods of diagnosing, treating and monitoring diabetic retinopathy | |
RU2014144701A (ru) | Способы воздействия на экспрессию гена TER1 | |
RU2014148258A (ru) | Способы воздействия на экспрессию гена ADA | |
RU2014142756A (ru) | Способы воздействия на экспрессию гена D4DR | |
RU2014142754A (ru) | Способы воздействия на экспрессию гена алкогольдегидрогеназы | |
RU2014148879A (ru) | Способы воздействия на экспрессию гена PRP |